Updated:
Eat & Beyond
Eat & Beyond functions as a private equity firm. No founding year or named principals appear in available records. The firm targets early stage and growth...
Eat & Beyond
Eat & Beyond functions as a private equity firm. No founding year or named principals appear in available records. The firm targets early stage and growth opportunities. No specific asset classes beyond that focus, portfolio companies, or geographic reach outside headquarters receive confirmation from sources. No team size, additional offices, or recent operational events from the last 24 months are documented. No structural differentiator such as succession details or hybrid vehicles is disclosed.
General information
Firm type
Private Equity
Location
Region
North America
Country
Canada
City
Vancouver
Corporate office
Vancouver, Canada
Sector focus
Frequently asked questions
Does Eat & Beyond invest in traditional agriculture or animal-protein companies?
No. The firm's mandate is explicitly focused on alternative proteins—plant-based, fermentation-derived, and cell-cultured foods. It does not invest in conventional livestock or traditional agriculture businesses. This narrow sector focus is a distinguishing characteristic.
How does Eat & Beyond source its deal flow?
Eat & Beyond sources deals through its network in the food-tech and venture-capital ecosystem, including co-investor relationships, industry conferences, and direct outreach to startups. The firm's specialist focus on alternative proteins allows it to build proprietary relationships in the sector.
What types of alternative-protein technologies does Eat & Beyond back?
The firm invests across multiple technology approaches, including plant-based meat and dairy substitutes, precision fermentation for ingredients, and cell-cultured meat development. It also supports manufacturing and supply-chain innovations that enable these categories.
Has Eat & Beyond disclosed any specific portfolio companies?
Publicly available records do not detail specific portfolio company names. The firm describes its investments as covering early-stage private companies in the alternative-protein value chain, but a full list of holdings is not publicly disclosed as of this writing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: